These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24016317)

  • 41. Case Report: Autoimmune Psychosis in Chromosome 22q11.2 Deletion Syndrome.
    Ciano-Petersen NL; Hamad-Cueto O; Drissi-Reyes H; Doña-Díaz Á; García-Martín G
    Front Immunol; 2021; 12():708625. PubMed ID: 34721378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS).
    Lim J; Rekhi G; Rapisarda A; Lam M; Kraus M; Keefe RS; Lee J
    Schizophr Res; 2015 May; 164(1-3):8-14. PubMed ID: 25818728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychiatric disorders and autism in young children with 22q11.2 deletion syndrome compared to children with idiopathic autism.
    Serur Y; Sofrin Frumer D; Daon K; Sobol-Havia D; Weinberger R; Shulman C; Gothelf D
    Eur Psychiatry; 2019 Jan; 55():116-121. PubMed ID: 30453155
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The dimensional structure of psychopathology in 22q11.2 Deletion Syndrome.
    Niarchou M; Moore TM; Tang SX; Calkins ME; McDonald-McGuinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
    J Psychiatr Res; 2017 Sep; 92():124-131. PubMed ID: 28433949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early language measures associated with later psychosis features in 22q11.2 deletion syndrome.
    Solot CB; Moore TM; Crowley TB; Gerdes M; Moss E; McGinn DE; Emanuel BS; Zackai EH; Gallagher S; Calkins ME; Ruparel K; Gur RC; McDonald-McGinn DM; Gur RE
    Am J Med Genet B Neuropsychiatr Genet; 2020 Sep; 183(6):392-400. PubMed ID: 32715620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Psychopathological features in Noonan syndrome.
    Perrino F; Licchelli S; Serra G; Piccini G; Caciolo C; Pasqualetti P; Cirillo F; Leoni C; Digilio MC; Zampino G; Tartaglia M; Alfieri P; Vicari S
    Eur J Paediatr Neurol; 2018 Jan; 22(1):170-177. PubMed ID: 29037749
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent developments in understanding the relationship between 22q11.2 deletion syndrome and psychosis.
    O'Rourke L; Murphy KC
    Curr Opin Psychiatry; 2019 Mar; 32(2):67-72. PubMed ID: 30394904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psychiatric comorbidity in children and adolescents with restless legs syndrome: a retrospective study.
    Pullen SJ; Wall CA; Angstman ER; Munitz GE; Kotagal S
    J Clin Sleep Med; 2011 Dec; 7(6):587-96. PubMed ID: 22171196
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review.
    Mosheva M; Korotkin L; Gur RE; Weizman A; Gothelf D
    Eur Child Adolesc Psychiatry; 2020 Aug; 29(8):1035-1048. PubMed ID: 30949827
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term effects of early treatment with SSRIs on cognition and brain development in individuals with 22q11.2 deletion syndrome.
    Mancini V; Maeder J; Bortolin K; Schneider M; Schaer M; Eliez S
    Transl Psychiatry; 2021 May; 11(1):336. PubMed ID: 34052829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis.
    Lin A; Wood SJ; Nelson B; Beavan A; McGorry P; Yung AR
    Am J Psychiatry; 2015 Mar; 172(3):249-58. PubMed ID: 25727537
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epilepsy and seizures in young people with 22q11.2 deletion syndrome: Prevalence and links with other neurodevelopmental disorders.
    Eaton CB; Thomas RH; Hamandi K; Payne GC; Kerr MP; Linden DEJ; Owen MJ; Cunningham AC; Bartsch U; Struik SS; van den Bree MBM
    Epilepsia; 2019 May; 60(5):818-829. PubMed ID: 30977115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Manic symptoms and behavioral dysregulation in youth with velocardiofacial syndrome (22q11.2 deletion syndrome).
    Aneja A; Fremont WP; Antshel KM; Faraone SV; AbdulSabur N; Higgins AM; Shprintzen R; Kates WR
    J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):105-14. PubMed ID: 17343558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prodromal symptoms in adolescents with 22q11.2 deletion syndrome and schizotypal personality disorder.
    Shapiro DI; Cubells JF; Ousley OY; Rockers K; Walker EF
    Schizophr Res; 2011 Jun; 129(1):20-8. PubMed ID: 21507614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with nonpsychotic psychiatric disorders.
    Gerstenberg M; Hauser M; Al-Jadiri A; Sheridan EM; Kishimoto T; Borenstein Y; Vernal DL; David L; Saito E; Landers SE; Carella M; Singh S; Carbon M; Jiménez-Fernández S; Birnbaum ML; Auther A; Carrión RE; Cornblatt BA; Kane JM; Walitza S; Correll CU
    J Clin Psychiatry; 2015 Nov; 76(11):e1449-58. PubMed ID: 26646040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Neurocognitive and psychiatric management of the 22q11.2 deletion syndrome].
    Demily C; Rossi M; Schneider M; Edery P; Leleu A; d'Amato T; Franck N; Eliez S
    Encephale; 2015 Jun; 41(3):266-73. PubMed ID: 25523123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms.
    Vorstman JAS; Morcus MEJ; Duijff SN; Klaassen PWJ; Heineman-de Boer JA; Beemer FA; Swaab H; Kahn RS; van Engeland H
    J Am Acad Child Adolesc Psychiatry; 2006 Sep; 45(9):1104-1113. PubMed ID: 16926618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Longitudinal perspectives on the psychosis spectrum in 22q11.2 deletion syndrome.
    Tang SX; Gur RE
    Am J Med Genet A; 2018 Oct; 176(10):2192-2202. PubMed ID: 29048724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis.
    Webb JR; Addington J; Perkins DO; Bearden CE; Cadenhead KS; Cannon TD; Cornblatt BA; Heinssen RK; Seidman LJ; Tarbox SI; Tsuang MT; Walker EF; McGlashan TH; Woods SW
    Schizophr Bull; 2015 Sep; 41(5):1066-75. PubMed ID: 26272875
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome.
    Kontoangelos K; Lazaratou E; Economou M; Yiannopoulou KG; Papageorgiou CC
    Psychopharmacol Bull; 2020 Mar; 50(1):35-39. PubMed ID: 32214520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.